glp 1 graves disease GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney glp 1 and graves disease

Exenatide, the first GLP-1RA approved in 2005, demonstrated clinical efficacy but its low homology with human GLP-1 and gastrointestinal side effects restricted widespread use (Muttenthaler et al., 2021)

TSH should be checked 6-8 weeks after initiating or adjusting levothyroxine, then annually once stable levels are achieved

Consider the medications as one piece of the puzzle, not the entire strategy

Restoring optimal growth hormone function through peptide therapy addresses these underlying deficiencies and creates conditions for improved sperm production

Following the withdrawal of albiglutide from the market in 2018 by the manufacturer for financial reasons (257), liraglutide, injectable semaglutide, and dulaglutide should currently be the preferred choices within this class for reducing cardiovascular events until further data are available (248)

Nat Rev Microbiol 19:5571